Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease

Journal of the Royal Society Interface

Volumn 11, Issue 92, 2014, Pages

  Meng, Fanlin ^a   Dai, Enyu ^a   Yu, Xuexin ^a   Zhang, Yan ^a   Chen, Xiaowen ^a   Liu, Xinyi ^a   Wang, Shuyuan ^a   Wang, Lihua ^a   Jiang, Wei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Bioinformatics; Drug; MicroRNA; Small molecule; Therapeutics

Indexed keywords

ANTIVIRAL AGENTS; BIOINFORMATICS; DISEASE CONTROL; GENE EXPRESSION; MOLECULES; NEURODEGENERATIVE DISEASES;

ALZHEIMER'S DISEASE; DRUG; MICRORNAS; SMALL MOLECULES; THERAPEUTICS;

RNA;

MESSENGER RNA; MICRORNA; AMANTADINE; DRUG; FUSED HETEROCYCLIC RINGS; QUINOLINE DERIVATIVE; QUINOSTATIN;

ALZHEIMER DISEASE; ARTICLE; GENE CONSTRUCT; GENE CONTROL; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRAIT; GENETIC VARIABILITY; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW; BIOINFORMATICS; BIOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; PHYSIOLOGY; SMALL MOLECULE; THERAPY;

ALZHEIMER'S DISEASE; BIOINFORMATICS; DRUG; MICRORNA; SMALL MOLECULE; THERAPEUTICS;

ALZHEIMER DISEASE; AMANTADINE; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICRORNAS; QUINOLINES; SMALL MOLECULE LIBRARIES;

EID: 84893102228     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2013.1057     Document Type: Article

References (67)

1. Goedert M, Spillantini MG. 2006 A century of Alzheimer's disease. Science 314, 777-781. (doi:10.1126/science.1132814)
2. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168. (doi:10.1016/j.jalz.2012.02.001)
3. Scheuner D et al. 1996 Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870. (doi:10.1038/nm0896-864)
4. De Strooper B, Iwatsubo T, Wolfe MS. 2012 Presenilins and gamma-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2, a006304. (doi:10.1101/cshperspect.a006304)
5. Mattson MP. 2004 Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. (doi:10.1038/nature02621)
6. Hardy J, Selkoe DJ. 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (doi:10.1126/science.1072994)
7. Bartel DP. 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297. (doi:10.1016/S0092-8674(04)00045-5)
8. Ashraf SI, McLoon AL, Sclarsic SM, Kunes S. 2006 Synaptic protein synthesis associated with memory is regulated by the RISC pathway in Drosophila. Cell 124, 191-205. (doi:10.1016/j.cell.2005.12.017)
9. Delay C, Mandemakers W, Hebert SS. 2012 MicroRNAs in Alzheimer's disease. Neurobiol. Dis. 46, 285-290. (doi:10.1016/j.nbd.2012.01.003)
10. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B. 2008 Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc. Natl Acad. Sci. USA 105, 6415-6420. (doi:10.1073/pnas.0710263105)
11. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT. 2008 The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 28, 1213-1223. (doi:10.1523/JNEUROSCI.5065-07.2008)
12. Garzon R, Marcucci G, Croce CM. 2010 Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775-789. (doi:10.1038/nrd3179)
13. Ling H, Fabbri M, Calin GA. 2013 MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847-865. (doi:10.1038/nrd4140)
14. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P. 2012 Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr. Cancer Drug Targets 12, 838-846. (doi:10.2174/ 156800912802429355)
15. Bhardwaj A, Singh S, Singh AP. 2010 MicroRNA-based cancer therapeutics: big hope from small RNAs. Mol. Cell Pharmacol. 2, 213-219. (doi:10.4255/ mcpharmacol.10.27)
16. Zhang S, Chen L, Jung EJ, Calin GA. 2010 Targeting microRNAs with small molecules: from dream to reality. Clin. Pharmacol. Ther. 87, 754-758. (doi:10.1038/clpt.2010.46)
17. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. 2008 Small-molecule inhibitors of microRNA miR-21 function. Angew. Chem. Int. Ed. Engl. 47, 7482-7484. (doi:10.1002/anie. 200801555)
18. Young DD, Connelly CM, Grohmann C, Deiters A. 2010 Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 132, 7976-7981. (doi:10.1021/ja910275u)
19. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. 2008 Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152. (doi:10.1038/nature06487)
20. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. 2010 Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70, 5923-5930. (doi:10.1158/0008-5472.CAN-10-0655)
21. Reid G et al. 2013 Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. (doi:10.1093/annonc/ mdt412)
22. Marhofer RJ, Oellien F, Selzer PM. 2011 Drug discovery and the use of computational approaches for infectious diseases. Future Med. Chem. 3, 1011-1025. (doi:10.4155/fmc.11.60)
23. Ou-Yang SS, Lu JY, Kong XQ, Liang ZJ, Luo C, Jiang H. 2012 Computational drug discovery. Acta Pharmacol. Sin. 33, 1131-1140. (doi:10.1038/aps.2012.109)
24. Iskar M, Zeller G, Zhao XM, van Noort V, Bork P. 2012 Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr. Opin. Biotechnol. 23, 609-616. (doi:10.1016/j.copbio.2011.11. 010)
25. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. 2011 Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77. (doi:10.1126/scitranslmed.3001318)
26. Dudley JT et al. 2011 Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76. (doi:10.1126/scitranslmed.3002648)
27. Iorio F et al. 2010 Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl Acad. Sci. USA 107, 14 621-14 626. (doi:10.1073/pnas.1000138107)
28. Jiang W et al. 2012 Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci. Rep. 2, 282. (doi:10.1038/srep00282)
29. Liang D, Han G, Feng X, Sun J, Duan Y, Lei H. 2012 Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS ONE 7, e40498. (doi:10.1371/journal.pone.0040498)
30. Liang WS et al. 2007 Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol. Genomics 28, 311-322. (doi:10.1152/physiolgenomics.00208.2006)
31. Liu ZP, Wang Y, Zhang XS, Chen L. 2010 Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer's disease brains. BMC Syst. Biol. 4(Suppl. 2), S11. (doi:10.1186/1752-0509-4-S2-S11)
32. Li X et al. 2012 Dissection of human MiRNA regulatory influence to subpathway. Brief Bioinform. 13, 175-186. (doi:10.1093/bib/bbr043)
33. Lamb J et al. 2006 The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935. (doi:10.1126/science.1132939)
34. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. 2009 PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623-W633. (doi:10.1093/nar/gkp456)
35. Zhao Y, Simon R. 2008 BRB-ArrayTools data Archive for human cancer gene expression: a unique and efficient data sharing resource. Cancer Inform. 6, 9-15.
36. Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ. 2010 Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS ONE 5, e8898. (doi:10.1371/journal.pone. 0008898)
37. Rahman SA, Bashton M, Holliday GL, Schrader R, Thornton JM. 2009 Small molecule subgraph detector (SMSD) toolkit. J. Cheminform. 1, 12. (doi:10.1186/1758-2946-1-12)
38. Knox C et al. 2011 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041. (doi:10.1093/nar/gkq1126)
39. Vassar R et al. 1999 Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741. (doi:10.1126/science.286.5440.735)
40. Stampfer MJ. 2006 Cardiovascular disease and Alzheimer's disease: common links. J. Intern. Med. 260, 211-223. (doi:10.1111/j.1365-2796.2006.01687.x)
41. Obisesan TO, Gillum RF, Johnson S, Umar N, Williams D, Bond V, Kwagyan J. 2012 Neuroprotection and neurodegeneration in Alzheimer's disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in African Americans. Int. J. Alzheimers Dis. 2012, 568382. (doi:10.1155/2012/568382)
42. de Toledo Ferraz Alves TC, Ferreira LK, Wajngarten M, Busatto GF. 2010 Cardiac disorders as risk factors for Alzheimer's disease. J. Alzheimers Dis 20, 749-763. (doi:10.3233/JAD-2010-091561)
43. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. 2006 A brain-specific microRNA regulates dendritic spine development. Nature 439, 283-289. (doi:10.1038/nature04367)
44. Long JM, Lahiri DK. 2011 MicroRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Commun. 404, 889-895. (doi:10.1016/j.bbrc.2010.12.053)
45. Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F. 2010 MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J. Biol. Chem. 285, 18 344-18 351. (doi:10.1074/jbc.M110.112664)
46. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A. 2007 A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220-1224. (doi:10.1126/science.1140481)
47. Yang J, Shamji A, Matchacheep S, Schreiber SL. 2007 Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem. Biol. 14, 371-377. (doi:10.1016/j.chembiol.2007.02.004)
48. Ma T et al. 2010 Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS ONE 5, e12845. (doi:10.1371/journal.pone.0012845)
49. Oddo S. 2012 The role of mTOR signaling in Alzheimer disease. Front. Biosci. 4, 941-952. (doi:10.2741/S310)
50. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. 2010 Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 285, 13 107-13 120. (doi:10.1074/jbc.M110.100420)
51. Bloomston M et al. 2007 MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901-1908. (doi:10.1001/jama.297.17.1901)
52. Ueda T et al. 2010 Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11, 136-146. (doi:10.1016/S1470-2045(09)70343-2)
53. Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, Gotz J. 2010 Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS ONE 5, e11070. (doi:10.1371/journal.pone.0011070)
54. Huey ED, Putnam KT, Grafman J. 2006 A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66, 17-22. (doi:10.1212/01.wnl.0000191304.55196.4d)
55. Meythaler JM, Brunner RC, Johnson A, Novack TA. 2002 Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J. Head Trauma Rehabil. 17, 300-313. (doi:10.1097/00001199-200208000-00004)
56. Hebert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN, Sergeant N, Buee L, De Strooper B. 2010 Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 19, 3959-3969. (doi:10.1093/hmg/ddq311)
57. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT. 2010 The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J. Mol. Biol. 402, 491-509. (doi:10.1016/j.jmb. 2010.07.051)
58. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassella E. 2009 miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69, 5553-5559. (doi:10.1158/0008- 5472.CAN-08-4277)
59. Bandi N, Vassella E. 2011 miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol. Cancer 10, 55. (doi:10.1186/1476-4598-10-55)
60. Hardeland R. 2012 Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. Scientific World Journal 2012, 640389. (doi:10.1100/2012/640389)
61. Tuzcu M, Baydas G. 2006 Effect of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur. J. Pharmacol. 537, 106-110. (doi:10.1016/j.ejphar.2006.03.024)
62. Ionov M, Burchell V, Klajnert B, Bryszewska M, Abramov AY. 2011 Mechanism of neuroprotection of melatonin against beta-amyloid neurotoxicity. Neuroscience 180, 229-237. (doi:10.1016/j.neuroscience.2011.02.045)
63. Rosales-Corral SA et al. 2012 Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J. Pineal Res. 52, 167-202. (doi:10.1111/j.1600-079X.2011.00937.x)
64. Furio AM, Brusco LI, Cardinali DP. 2007 Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J. Pineal Res. 43, 404-409. (doi:10.1111/j.1600-079X.2007.00491.x)
65. Wu YH, Swaab DF. 2007 Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 8, 623-636. (doi:10.1016/j.sleep.2006.11.010)
66. Xu Y et al. 2010 MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophr. Res. 119, 219-227. (doi:10.1016/j.schres.2010.02.1070)
67. Cogswell JP et al. 2008 Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 14, 27-41. (Pubitemid 352039013)